Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Afamitresgene autoleucel by Adaptimmune Therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma): Likelihood of Approval
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)....
Afamitresgene autoleucel by Adaptimmune Therapeutics for Neuroblastoma: Likelihood of Approval
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Neuroblastoma. According to GlobalData, Phase...
Afamitresgene autoleucel by Adaptimmune Therapeutics for Osteosarcoma: Likelihood of Approval
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Osteosarcoma. According to GlobalData, Phase...
Afamitresgene autoleucel by Adaptimmune Therapeutics for Round Cell Liposarcoma: Likelihood of Approval
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Round Cell Liposarcoma. According to...
ADPA-2AFP by Adaptimmune Therapeutics for Lung Cancer: Likelihood of Approval
ADPA-2AFP is under clinical development by Adaptimmune Therapeutics and currently in Phase I for Lung Cancer. According to GlobalData, Phase...
ADPA-2AFP by Adaptimmune Therapeutics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
ADPA-2AFP is under clinical development by Adaptimmune Therapeutics and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...
Afamitresgene autoleucel by Adaptimmune Therapeutics for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer....
Afamitresgene autoleucel by Adaptimmune Therapeutics for Myxoid Liposarcoma: Likelihood of Approval
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Myxoid Liposarcoma. According to GlobalData,...
ADPA-2AFP by Adaptimmune Therapeutics for Pancreatic Cancer: Likelihood of Approval
ADPA-2AFP is under clinical development by Adaptimmune Therapeutics and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
ADPA-2AFP by Adaptimmune Therapeutics for Gastric Cancer: Likelihood of Approval
ADPA-2AFP is under clinical development by Adaptimmune Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
ADPA-2AFP by Adaptimmune Therapeutics for Malignant Neoplasms: Likelihood of Approval
ADPA-2AFP is under clinical development by Adaptimmune Therapeutics and currently in Phase I for Malignant Neoplasms. According to GlobalData, Phase...
ADPA-2AFP by Adaptimmune Therapeutics for Neuroendocrine Tumors: Likelihood of Approval
ADPA-2AFP is under clinical development by Adaptimmune Therapeutics and currently in Phase I for Neuroendocrine Tumors. According to GlobalData, Phase...
Letetresgene autoleucel by Adaptimmune Therapeutics for Myxoid Liposarcoma: Likelihood of Approval
Letetresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Myxoid Liposarcoma. According to GlobalData,...
Letetresgene autoleucel by Adaptimmune Therapeutics for Round Cell Liposarcoma: Likelihood of Approval
Letetresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Round Cell Liposarcoma. According to...
Letetresgene autoleucel by Adaptimmune Therapeutics for Synovial Sarcoma: Likelihood of Approval
Letetresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Synovial Sarcoma. According to GlobalData,...
Afamitresgene autoleucel by Adaptimmune Therapeutics for Synovial Sarcoma: Likelihood of Approval
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Pre-Registration for Synovial Sarcoma. According to GlobalData, Pre-Registration...